There are also “thunder explosions” in stocks. One is “sweeping the floor Siasun Robot&Automation Co.Ltd(300024) Mao” Beijing Roborock Technology Co.Ltd(688169) . The performance growth rate has dropped to 2%, and there will be a reduction of more than 10% including Lei Jun; One Jilin Zixin Pharmaceutical Industrial Co.Ltd(002118) , the performance loss continues to expand, with a loss of more than 500 million.
The latest number of shareholders shows that the number of shareholders of the two stocks exceeds 100000. Already suffering from the continuous decline of stock price and ushering in bad news, Beijing Roborock Technology Co.Ltd(688169) comments can be seen that netizens are very depressed and expressing dissatisfaction.
Beijing Roborock Technology Co.Ltd(688169) decline in performance growth
On February 24, Beijing Roborock Technology Co.Ltd(688169) announced that the operating revenue in 2021 was 5.837 billion yuan, an increase of 28.84% year-on-year; The net profit attributable to the owners of the parent company was 1.402 billion yuan, a year-on-year increase of 2.4%.
In the first three quarters of 2021, the net profit of Beijing Roborock Technology Co.Ltd(688169) was 1.016 billion yuan, a year-on-year increase of 12.98%. The growth rate declined in the fourth quarter. Compared with the net profit growth of 75% and 155% in 2020 and 2019 respectively, it is a sharp decline.
Beijing Roborock Technology Co.Ltd(688169) said that due to the shortage of global transportation capacity caused by the epidemic and other factors, there were more container detention, ship jumping and poor transportation cycle, which had a certain negative impact on the growth of the company’s revenue.
From the previous prediction of securities companies, the performance of Beijing Roborock Technology Co.Ltd(688169) is also lower than the expectation of securities companies. Many securities companies predict that the net profit of Beijing Roborock Technology Co.Ltd(688169) will reach 1.5 billion yuan in 2021. In February this year, UBS Securities also predicted a net profit of 1.554 billion yuan in Beijing Roborock Technology Co.Ltd(688169) 2021.
The share price of has halved, and Lei Jun, the shareholder, and other executives have to reduce their holdings of
When the performance growth rate declined, Beijing Roborock Technology Co.Ltd(688169) also threw out a “big killer”. Jinmi and Dong Jiangao, controlled by Lei Jun, plan to reduce their holdings by no more than 10.752%, and the reduction is also very small. With the current market value of Beijing Roborock Technology Co.Ltd(688169) 44.9 billion yuan, the market value of this wave of reduction is as high as nearly 5 billion yuan.
The announcement shows that Tianjin Jinmi investment, stone age, Wan Yunpeng, Wang Xuan and Sun Jia plan to reduce their holdings. Tianyancha shows that the actual controller behind Jinmi investment is Lei Jun, a well-known entrepreneur, the stone age is an employee stock ownership platform of Beijing Roborock Technology Co.Ltd(688169) , and WAN Yunpeng, Wang Xuan and Sun Jia are the directors, supervisors and senior managers of the company.
That is, Lei Jun, the boss of Xiaomi company who has important support for Beijing Roborock Technology Co.Ltd(688169) sweeping Siasun Robot&Automation Co.Ltd(300024) , Beijing Roborock Technology Co.Ltd(688169) company executives and Beijing Roborock Technology Co.Ltd(688169) employees, all want to reduce their holdings one after another.
Since its high in June last year, Beijing Roborock Technology Co.Ltd(688169) has halved its share price, from a maximum of 1492 yuan to less than 700 yuan, leaving a market value of 44.9 billion yuan.
netizen: it’s easy. If the share price falls below the position, we have to make up
Beijing Roborock Technology Co.Ltd(688169) the share price was halved, and there was another bad attack. Netizens also had a heated discussion. Some netizens said that under the tragic share price, they still had to make up for the knife accurately.
The loss of Jilin Zixin Pharmaceutical Industrial Co.Ltd(002118) expanded, with a loss of more than 500 million in 2021
Jilin Zixin Pharmaceutical Industrial Co.Ltd(002118) with a loss of 341 million yuan in the first three quarters of 2021, the annual loss continued to expand to more than 500 million yuan. Jilin Zixin Pharmaceutical Industrial Co.Ltd(002118) announced that in 2021, the company achieved a total operating revenue of 250 million yuan, a decrease of 12.44% over the same period of last year; The net profit attributable to the shareholders of the listed company was -555 million yuan.
Jilin Zixin Pharmaceutical Industrial Co.Ltd(002118) said that there was no significant change in the company’s business structure in 2021, but the company was facing the adverse environment and competitive pressure of the pharmaceutical industry. In the past 2020-2021 years, China’s main business has been seriously affected by New Coronavirus’s epidemic situation.
In 2021, with the gradual control of the epidemic situation in China and the introduction of a series of national policies and measures to support the resumption of work and production and stabilize the economy, and with the efforts of the board of directors of the company, the company signed relevant agreements with Sinopharm Zhaoxiang (Changchun) Pharmaceutical Co., Ltd. to ensure the production of raw materials. Although the production and operation of the company were gradually restored, the company was still in the recovery period in 2021, This led to the company’s expected loss in 2021.
